Citations

Clear

16280 citation(s) found for "Yu, David".

Trends in Spinal Pain Procedure Volumes and Reimbursements: An Analysis of 20 Years of Medicare Data
Gajjar, Avi A. , Dombrovsky, David, Stonnington, Henry O. , Polavarapu, Hanish , George, Derek D. , Wakim, Andre, Harland, Tessa , Dombrovsky, David A , George, Derek D , Mansfield, Kevin , Singh, Rohin , Koester, Stefan Wolfgang , Wakim, Andre

Mayo Clinic

Pain Practice | May 21, 2025 | Volume: 25 | Issue: 5 | Pages: No page available

10.1111/papr.70043 | PMID 40395062 Get It

ABSTRACT Introduction Chronic back/neck pain costs the United States around 250 billion dollars annually. Treatment strategies include medication, physical therapy, and specialized procedures. This study aimed to investigate the trends in procedural frequency and Medicare reimbursement rates for common back pain procedures. Methods Data from 2000 to 2020 were extracted from Medicare Part B National Summary Data files, using Current Procedural Terminology (CPT) codes to identify reimbursement for cervical/thoracic and lumbar/sacral epidural injections, radiofrequency ablation, facet joint injections, and spinal cord stimulators (both percutaneous and paddle). Key metrics included annual total physician charges, reimbursements, and the number of procedures performed. Results From 2000 to 2020, 53,208,205 pain procedures were performed. The most common was lumbar/sacral epidural injections, followed by facet joint injections and radiofrequency ablations. Paddle SCS placement was the least common. Percutaneous SCS had the greatest volume growth, increasing from 3595 to 111,172 [+2992%], followed by lumbar/sacral epidural injections with 118,884 to 1,965,445 [+1553%], and cervical/thoracic epidural injections, 22,480–348,642 [+1451%]. All procedures saw a significant increase in volume except for facet joint injections. Inflation‐adjusted reimbursement per service also increased, with paddle SCS demonstrating the largest increase ($618–$2960 [+379.0%]), followed by percutaneous SCS ($353–$1428 [+304.5%]) and cervical/thoracic epidural injections ($128–$153 [+19.5%]). Conclusions Pain management procedures have increased in volume and reimbursement over the last 20 years. This increased reimbursement may allow for broader access to these procedures compared to prior decades and support a shift from traditional and more invasive surgical procedures to minimally invasive treatments for chronic pain patients.
Contemporary Biology, Management, and Outcomes of Renal Medullary Carcinoma in Children and Adults: A Pediatric Surgical Oncology Research Collaborative Study
Beckhorn, Catherine B , Malek, Marcus M. , Lovvorn, Harold N. , McKay, Katlyn G. , Kontchou, Nelly‐Ange T. , Kastenberg, Zachary J. , Hoyt, David , Roach, Jonathan P. , Myers, Emily K. , Cost, Nicholas G. , Mullapudi, Bhargava , Marchese, Charles R. , Jensen, Amanda , Lundstedt, John, Brungardt, Joseph G. , Davidoff, Andrew M. , Piché, Nelson , Craig, Brian T. , Schuh, Jennifer M , Cromeens, Barrett P., Castle, Shannon L. , Mello, Kathryn Bandeira de, Short, Joshua , Petroze, Robin T. , Rajaval, Shay, Thompson, Grace R., Fialkowski, Elizabeth , Martchenke, Nathan, Rich, Barrie S. , Glick, Richard D. , Doyle, Kathleen , Abril, Paige, Seemann, Natashia M. , Davidson, Jacob B., Wilson, Claire A. , Joshi, Devashish , Stellon, Michael , Newman, Erika A. , Hammoud, Maya M. , Williams, Keyonna M , Grant, Christa N. , Gorgy, Merit , Polites, Stephanie F. , Debertin, Julia , Cameron, Danielle B. , Stetson, Alyssa , Lee, William G. , Barkhordar, Aaron, Austin, Mary T. , Coakley, Brian A. , Kahan, Anastasia M , Murphy, Joseph T., Pitonak, Michael, Boehmer, Chloé , Tracy, Elisabeth T. , Kastenberg, Zachary J , Hoyt, David W , Cost, Nicholas G , Marchese, Charles R , Lautz, Timothy , Lundstedt, John , Brungardt, Joseph G , Talbot, Lindsay J , Murphy, Andrew J , Aldrink, Jennifer H , Piche, Nelson , Mannava, Sindhu V , Fialkowski, Elizabeth A , Rich, Barrie S , Seemann, Natashia M , Stellon, Michael , Dimmer, Alexandra M , Williams, Keyonna , Barkhordar, Aaron , Beckhorn, Catherine , Tracy, Elisabeth T , Malek, Marcus M , Kahan, Anastasia Morgan , Leraas, Harold J. , Lautz, Timothy B. , Carter, Michela M. , Dasgupta, Roshni , Murphy, Andrew J. , Aldrink, Jennifer H. , Mansfield, Sara A. , Lal, Dave R. , López, Adriana , Mattei, Peter , Rothstein, David H. , Fowler, Kathryn L. , Brown, Erin G. , Abril, Paige, Rinehardt, Hannah , Le, Hau D. , Ahmed, Tamer, Kim, Eugene S. , Pitonak, M.

Mayo Clinic

Pediatric Blood & Cancer | May 21, 2025 | Volume: 72 | Issue: 8 | Pages: No page available

10.1002/pbc.31774 | PMID 40394815 Get It

ABSTRACTBackgroundRenal medullary carcinoma (RMC) is an aggressive tumor associated with sickle cell trait. Despite treatment advances for other rare renal tumors, RMC survival remains poor. We aimed to describe the contemporary management and survival of children and adults with RMC.ProcedureIn this multicenter retrospective cohort study, Pediatric Surgical Oncology Research Collaborative sites searched their databases for patients diagnosed with RMC (2000–2022). Descriptive statistics were calculated and survival analyses performed using Kaplan–Meier and Cox regression.ResultsThirty‐four patients with RMC were identified. Median age was 19 years (IQR: 15–28; range: 7–52). Most were male (24/34; 71%), Black (27/32; 84%), had sickle cell trait or disease (30/33; 91%), presented with metastatic disease (27/34; 79%), and were symptomatic at presentation (32/34; 94%). Median overall survival (OS) was 24 months from diagnosis (16 months for children, 28 months for adults, p = 0.6). Receipt of platinum‐based chemotherapy (23/34; 68%) was associated with significantly higher OS than other regimens (35 vs. 5 months, p < 0.001). Nephrectomy (24/34; 71%) was associated with significantly improved OS compared with non‐operative management (34 vs. 7 months, p = 0.001). Immunotherapy, targeted therapy, or radiation therapy were not associated with significant differences in OS, nor were age, sex, race, sickle cell status, SMARCB1/INI‐1, stage, nephrectomy approach, retroperitoneal lymph node dissection, gross residual disease, margins, or tumor size.ConclusionsRMC survival remains poor despite newer therapies. Nephrectomy and platinum‐based chemotherapy should be considered in locally advanced and metastatic disease. Coordinated international cooperative group studies are needed to meaningfully improve RMC survival.
Phospho-RPA2 predicts response to platinum and PARP inhibitors in homologous recombination–proficient ovarian cancer
Compadre, Amanda, Drexler, Rebecca, Loeb, Megan, Rodriguez, Kevin, Brill, Joshua, Harrington, Shariska P. , Sandoval, Carmen, Sanders, Brooke E. , Kuroki, Lindsay M. , Hagemann, Andrea R. , Powell, Matthew A. , Walts, Ann E. , Karlan, Beth, Oršulić, Sandra , Zhao, Peinan , Khabele, Dineo , Harrington, Shariska, Schab, Angela M. , Compadre, Amanda J. , Drexler, Rebecca, McCourt, Carolyn Kay , Thaker, Premal H. , Mutch, David G. , Serra, Violeta , Hagemann, Ian S. , Fuh, Katherine Cynthia , Sun, Lulu , Verma, Priyanka , Lomonosova, Elena , Mullen, Mary Margaret

Mayo Clinic

Journal of Clinical Investigation | May 20, 2025 | Volume: 135 | Issue: 13 | Pages: No page available

10.1172/jci189511 | PMID 40392598 Get It

BACKGROUND Treatment of tubo-ovarian high-grade serous carcinoma (HGSC) includes cytoreductive surgery, platinum-based chemotherapy, and often poly(ADP-ribose) polymerase (PARP) inhibitors. While homologous recombination (HR) deficiency is a well-established predictor of therapy sensitivity, over 50% of HR-proficient HGSCs also exhibit sensitivity. Currently, there are no biomarkers to identify which HR-proficient HGSCs will be sensitive to standard-of-care therapy. Replication stress may serve as a key determinant of response. METHODS We evaluated phospho–RPA2-T21 (p-RPA2) foci via immunofluorescence as a biomarker of replication stress in formalin-fixed, paraffin-embedded HGSC samples collected at diagnosis from patients treated with platinum chemotherapy (discovery cohort, n = 31; validation cohort, n = 244) or PARP inhibitors ( n = 63). Recurrent HGSCs ( n = 38) were also analyzed. p-RPA2 score was calculated using automated imaging analysis. RESULTS Samples were defined as p-RPA2-high if more than 16% of cells had ≥2 p-RPA2 foci on automated analysis. In the discovery cohort, HR-proficient, p-RPA2-high HGSCs demonstrated significantly higher rates of a chemotherapy response score of 3 to platinum chemotherapy than HR-proficient, p-RPA2-low HGSCs. In the validation cohort, patients with HR-proficient, p-RPA2-high HGSCs had significantly longer survival after platinum treatment than those with HR-proficient, p-RPA2-low HGSCs. Additionally, the p-RPA2 assay effectively predicted survival outcomes in patients treated with PARP inhibitors and in recurrent HGSC samples. CONCLUSION Our study underscores the importance of considering replication stress markers, such as p-RPA2, alongside HR status in therapeutic planning. This approach has the potential to increase the number of patients receiving effective therapy while reducing unnecessary toxicity. FUNDING The Reproductive Scientist Development Program, GOG Foundation, Pilot Translational and Clinical Studies function of the Washington University Institute of Clinical and Translational Sciences, the Foundation for Barnes-Jewish Hospital, Washington University School of Medicine Dean’s Scholar Program, The Cancer Biology Pathway Training Grant (5T32CA113275-17), The Lucy, Anarcha, and Betsey (L.A.B.) Award from the Department of Obstetrics and Gynecology at Washington University School of Medicine, and Veterans Affairs Office of Research and Development (I01BX006020).
Novel Benchmark for Robotic Liver Resection – Bridging Tradition with Innovation
Pfister, Matthias , Ma, Yong , Yang, Guangchao, Li, Linqiang , Song, Xuan , Venezia, Raphael, Jeddou, Heithem , Floc’h, Bastien Le, Valverde, A. , Péru, N. , Pessaux, Patrick, Salloum, Chady , Blanc, P., Scatton, Olivier , Tzedakis, Stylianos , Fuks, David , Chaoui, Ismaël, Silva, Silvia Gomes da, Sobral, M., Centonze, Leonardo , Zhu, Zhu , Ratti, Francesca, Rompianesi, Gianluca , Shah, Jimmy, Wakabayashi, Taiga , Coelho, Fabrício Ferreira , Castillo‐Flores, Samy , Viti, Virginia, Boggi, Ugo , Han, Ho-Seong, Panaro, Fabrizio , Wakabayashi, Go, Ielpo, Benedetto , Mejia, Alejandro , Troisi, Roberto I., Choi, Gi Hong , Liu, Rong , Sucandy, Iswanto, Rela, Mohamed , D’Hondt, Mathieu , Bröering, Dieter C. , Clavien, Pierre‐Alain , Li, Zhihao , Dong, Yawen , Clavien, Pierre-Alain , Centonze, Leonardo , Li, Zhihao , Li, Zhihao, Raptis, Dimitri , Song, Xuan, Millet, Guillaume, Truant, Stéphanie , Venezia, Raphael, Pessaux, Patrick , Giannone, Fabio , Mabrut, Jean‐Yves , Mohkam, Kayvan , Cunha, António Sá , Roy, Bertrand Le , Goumard, Claire , Fuks, David , Rammohan, Ashwin , Silva, Silvia Gomes da, López‐López, Víctor , Ratti, Francesca, Marino, Rebecca , Müller, Philip C , Lee, Bo Ram , Kato, Yutaro , Polanco, Patricio Marcelo , Goh, Brian K P , Cheung, Tan To , Efanov, Mikhail G. , Machado, Marcel Cerqueira César , Herman, Paulo , Müller-Stich, Beat Peter , Starlinger, Patrick , Martinie, John B. , Aldrighetti, Luca , Chen, Guodong , Robles, R , Benedetto, Fabrizio Di , Marques, Hugo P. , Sucandy, Iswanto , Brustia, Raffaele , Soubrane, Olivier

Mayo Clinic

Annals of Surgery | May 20, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/sla.0000000000006759 | PMID 40391433 Get It

Objective: To establish benchmark cutoffs for robotic liver resection (R-LR), encompassing both major and minor resections, and to determine the impact of patient selection on outcomes. Background: R-LR is a key advancement in minimally invasive liver surgery but lacks standardized benchmarks, especially for minor resections. While guidelines endorse R-LR, its role in optimizing outcomes remains unclear. This study establishes the first benchmarks for R-LR, enabling comparisons across surgical modalities and refining patient selection. Methods: This retrospective, multicenter study analyzed consecutive adult patients undergoing R-LR at 30 international centers (2020–2023). Benchmark centers had an annual case volume of ≥15 R-LR. Benchmark criteria included ASA ≤2, no major comorbidities, no prior liver resections, and Child-Pugh A status. Benchmark cutoffs for 14 key outcomes were set at the 50th and 75th percentiles of median values across benchmark centers. Multivariable logistic regression identified predictors of textbook outcomes. Results: Eighteen high-volume centers contributed 4028 cases with 2632 (65.3%) meeting benchmark criteria. Malignancy was the indication in 29.6%, most commonly hepatocellular carcinoma followed by colorectal liver metastases. Major liver resection was performed in 42.6%. The distribution of Iwate difficulty scores was low (25.4%), intermediate (53.9%), advanced (15.9%), and expert (4.9%). Benchmark cutoffs were established for minor and major resection, and stratified by Iwate low (0-3), intermediate (4-6) and high (7-12): Open conversion (≤6.5% minor, ≤10.5% major), major complications within 90 days (≤5.2% minor, ≤16.7% major), R1 resection (≤9.2% minor, ≤6.7% major). Benchmark cases performed at low-volume centers were able to achieve outcomes within the corresponding benchmark cutoffs. In fact, patient selection reflected by the proportion of benchmark patients, rather than case volume, was associated with textbook outcomes. Conclusions: This study defines R-LR benchmarks, emphasizing patient selection over center volume for optimal outcomes. Benchmark cutoffs guide training and support the expansion of R-LR.
A multicenter, prospective, single‐arm study of 60‐day peripheral nerve stimulation of the occipital nerves for the treatment of headache
Gutierrez, Genaro, McCormick, Zachary L. , Engle, Mitchell, Gilmore, Christopher A , Pingree, Matthew J. , Pope, Jason E. , DiBenedetto, David , Kissoon, Narayan , Sayal, Puneet, Zurn, Claire A. , Boggs, Joseph W. , DiBenedetto, David J , Kissoon, Narayan R , Crosby, Nathan D , Boggs, Joseph W , Pingree, Matthew , McCormick, Zachary L , Crosby, Nathan D.

Mayo Clinic

Headache: The Journal of Head and Face Pain | May 20, 2025 | Volume: 65 | Issue: 10 | Pages: 1776-1787

10.1111/head.14948 | PMID 40391557 Get It

Abstract Objective The aim of this study was to evaluate the efficacy and safety of a 60‐day peripheral nerve stimulation (PNS) treatment targeting the occipital nerves for reducing pain and improving function in individuals diagnosed with cervicogenic headache or occipital neuralgia. Background Headache conditions are prevalent and commonly disabling, and conventional therapeutic strategies are often insufficient. Development of a percutaneous 60‐day PNS treatment has created new opportunities to evaluate PNS of the occipital nerves. Methods This study was an institutional review board‐approved, multicenter, prospective, single‐arm study that enrolled participants from October 2022 to March 2024. Participants with cervicogenic headache or occipital neuralgia received a 60‐day PNS treatment targeting the occipital nerves. The primary endpoint was the proportion reporting clinically significant (≥30%) reductions in average pain and/or pain interference at end of treatment (EOT). Additional analysis included the proportion of participants with ≥50% reduction in average pain intensity and/or pain interference and additional outcomes including Patient Global Impression of Change, six‐item Headache Impact Test, and Neck Disability Index. Results At EOT, 90% of participants (18/20) met the primary endpoint. Further, 85% (17/20) and 83% (15/18) reported ≥50% reductions in pain and/or pain interference at EOT and 3 months, respectively. Clinically meaningful improvements were observed in functional and headache‐related disability and quality‐of‐life measures. All study‐related adverse events were non‐serious. Conclusion Most participants reported significant reductions in pain and/or pain interference following 60‐day PNS targeting the occipital nerves. Outcomes through 3 months demonstrate how 60‐day PNS offers an effective approach for the treatment of headache.
Significant Microvascular Abnormalities Present in Autonomic Nervous System Dysfunction: Results of a Cross-Sectional Study
Mumtaz, Sehreen , Arca, Karissa N., Majithia, Vikas , Cheshire, William P. , Hodge, David, Berianu, Florentina , Arca, Karissa, Cheshire, William P , Majithia, Vikas , Mumtaz, Sehreen

Mayo Clinic

Biomedicines | May 20, 2025 | Volume: 13 | Issue: 5 | Pages: 1242

10.3390/biomedicines13051242 | PMID 40427067 Get It

Purpose: The prevalence and phenotype of capillaroscopic abnormalities in patients with autonomic nervous system dysfunction have not yet been investigated. Multiorgan involvement in dysautonomia entails abnormal vasoreactivity. We aim to correlate the diagnosis of autonomic dysfunction with certain clinical manifestations, which may provide prognostic or diagnostic information using a noninvasive technique, i.e., nailfold video capillaroscopy (NVC). Methods: Patients with autonomic nervous system dysfunction were recruited from rheumatology and neurology clinics with voluntary NVC procedures from 31 January 2024 to 10 January 2024, and a comparison with normal controls was performed. Additional recorded information include demographics and diagnoses of autonomic dysfunction types by autonomic testing, including, but not limited to, the following: reflex screen, sweat test, Valsalva maneuver, nerve fiber density, electromyography (EMG), serology, and history of autoimmune diseases. NVC was performed on a total of 27 patients. This study was approved by the Mayo Clinic Institutional Review Board. Results: The autonomic dysfunction group consisted of small-fiber neuropathy (37%), orthostatic hypotension (48%), autonomic neuropathy (30%), limited autonomic neuropathy (7%), postural orthostatic tachycardia syndrome (POTS) (7%), and connective tissue disease (7%), among other types. Patients with autonomic dysfunction had statistically significant increases in microhemorrhages, dilated capillaries, and ramifications when compared to controls. Conclusions: Autonomic dysfunction was associated with statistically significant microvascular abnormalities compared to normal controls with a distinct NVC pattern. There was a statistically significant correlation between age and BMI with microvascular abnormalities. Here, we demonstrate the diagnostic potential of NVC in autonomic dysfunction and advocate for further study of capillary structures in autonomic dysfunction.
Impact of systemic imaging surveillance on survival from metastatic uveal melanoma
Ryan, Velvet Van, Zahrieh, David M. , Van Ryan, Velvet, Strand, Carrie , Churchill, Robert , Dalvin, Lauren A. , Dudek, Arkadiusz Z.

Mayo Clinic

Melanoma Research | May 19, 2025 | Volume: 35 | Issue: 4 | Pages: 268-275

10.1097/cmr.0000000000001042 | PMID 40387899 Get It

The National Comprehensive Cancer Network (NCCN) recommended surveillance imaging intervals for uveal melanoma (UM) based on the risk of distant metastasis. The objective of this research is to evaluate if patients, treated at our tertiary cancer center, who had scans consistent with these guidelines, had improved overall survival (OS). This was a single-center, retrospective study of UM patients, who developed metastatic disease. Patients were grouped into risk-of-metastasis cohorts (low, medium, and high-risk) based on the UM NCCN guidelines v1.2023. The frequency of scans was reported within annual intervals for 5 years within the low-risk cohort and for 10 years within the medium-risk cohort, and within 6-month intervals for the first 5 years and then annually in years 6–10 within the high-risk cohort. Conditional landmark analyses were used to evaluate the relationship between OS and consistency with guidelines. Scan frequency was evaluated against socioeconomic status. Of the 740 UM patients identified (1997–2020), 110 experienced metastasis and comprised our analysis population (20 low-risk; 67 medium-risk; and 23 high-risk). The median time to death (95% confidence interval) from diagnosis of metastasis was similar between the low, medium, and high-risk cohorts at 1.2 (1.0, 2.0), 2.0 (1.7, 2.6), and 1.6 (1.3, 2.3) years, respectively. For each cohort, the OS results were similar between those who followed guidelines vs. not at each annual landmark time. Living in disadvantaged areas did not impact imaging frequency (all P > 0.05). Imaging at intervals outlined by the NCCN guidelines v1.2023 did not impact OS for patients who developed metastatic UM.
0831 Effectiveness and Safety of Low-Sodium Oxybate in Participants with Narcolepsy: Results from the DUET Study
Schneider, Logan , Ruoff, Chad , Nichols, Deborah A. , Steininger, Teresa L. , Fuller, Douglas S. , Akerman, Sarah , Alexander, Jessica, Whalen, Marisa, Cairns, Alyssa , Ruoff, Chad M , Plante, David T. , Kirby, M

Mayo Clinic

SLEEP | May 19, 2025 | Volume: 48 | Issue: Supplement_1 | Pages: A360-A360

10.1093/sleep/zsaf090.0831 Get It

Abstract Introduction Jazz DUET (Develop hypersomnia Understanding by Evaluating low-sodium oxybate Treatment) is a phase 4, prospective, multicenter, single-arm, multiple-cohort, open-label study (NCT05875974) assessing the effectiveness of low-sodium oxybate (LXB; Xywav®) treatment on daytime and nighttime symptoms in participants with narcolepsy (type 1 [NT1] or 2 [NT2]) or idiopathic hypersomnia. Data presented are from the narcolepsy cohort. Methods DUET included a screening period (with 2-week washout for current oxybate users), 8-day baseline (BL) period, 2- to 8-week LXB titration period, 2-week stable-dose period, 8-day end-of treatment (EOT) period, and 2-week safety follow-up. The primary endpoint was change in Epworth Sleepiness Scale (ESS) score from BL to EOT. Key secondary endpoints for the narcolepsy cohort included change in polysomnography parameters: total shifts from deeper to lighter sleep stages, stage N3 sleep duration (minutes), and number of awakenings. Additional endpoints included Patient Global Impression of Change (PGIc)–overall narcolepsy disease. Primary and key secondary endpoints were controlled for multiplicity with sequential testing; other P-values are considered nominal. Results Fifty-five narcolepsy participants enrolled and were dosed with LXB (NT1, n=26; NT2, n=29); 13 transferred to another cohort and 34 were completers (NT1, n=16; NT2, n=18). Enrolled participants were mostly female (72.7%) and White (80.0%); mean (SD) age was 33.4 (12.9) years (NT1=34.6 [12.6]; NT2=32.4 [13.2]). For completers, least-squares mean (LSM) (SE) changes in ESS score were −7.7 (0.9), P&lt;.0001, overall; NT1=−6.5 (1.4), P&lt;.0001; NT2=−8.8 (1.3), P&lt;.0001. Compared with BL, sleep architecture at EOT showed fewer deeper to lighter sleep stage shifts (LSM [SE]: −13.1 [2.9], P&lt;.0001, overall; NT1=−13.9 [4.3], P=0.0029; NT2=−12.3 [4.1], P=0.0050); increased stage N3 sleep (minutes) (45.0 [8.8], P&lt;.0001, overall; NT1=49.8 [13.0], P=0.0006; NT2=40.8 [12.3], P=0.0023); and fewer awakenings (−3.2 [0.9], P=0.0015, overall; NT1=−4.1 [1.4], P=0.0056; NT2=−2.3 [1.3], P=0.0771). Most participants (93.3%, n=30; NT1, 86.7%, n=15; NT2, 100%, n=15) reported improvement (very much, much, minimally) in overall narcolepsy disease on PGIc. Treatment-emergent adverse events were consistent with the known safety profile of LXB. Conclusion Participants with NT1 and NT2 taking open-label LXB showed improvements in daytime sleepiness (decreased ESS scores) and reduced symptom burden (improved PGIc), which paralleled improvements in sleep architecture and disruption. Support (if any) Jazz Pharmaceuticals
0609 Cardiovascular Disease Risk Factors in Former National Football League Players: Impact of Obstructive Sleep Apnea
Greenlund, Ian M. , Forgione, Marc A., Perryman, Jonathan, Gergen, David, Martinez-Ferrate, Rodolfo, Covassin, Naima , Bukartyk, Jan , Roberts, Arthur J., Perryman, Jonathan, Bock, Joshua M. , Somers, Virend K.

Mayo Clinic

SLEEP | May 19, 2025 | Volume: 48 | Issue: Supplement_1 | Pages: A266-A266

10.1093/sleep/zsaf090.0609 Get It

Abstract Introduction Cardiovascular disease (CVD) remains the leading cause of death in the United States. We previously showed a high prevalence of obstructive sleep apnea (OSA) among former National Football League (NFL) players. Further, we hypothesized that post-career OSA impacts CVD risk among retired professional athletes, even though these former NFL players are often near peak physical fitness for a significant portion of their lifespan. The Living Heart Foundation Heart-Obesity-Prevention-Education Group aimed to provide an in-depth health assessment for CVD risk factors among former NFL players to examine the role of OSA on blood pressure (BP) and echocardiographic measurements. Methods Forty-three former NFL players completed an at-home sleep study and outpatient health assessment to determine CVD risk including office BP and transthoracic echocardiogram (TTE) measurements. Seated BP readings were made in triplicate, TTE measurements, including ejection fraction, left atrial size, left ventricular size and thickness, and ascending aortic diameter, were obtained in 17 former NFL players without OSA (age: 46±10 years, BMI: 32±5 kg/m2, apnea-hypopnea index: 3±1 events/hour) and 26 with OSA (age: 51±9 years, BMI: 33±5 kg/m2, apnea-hypopnea index: 17±12 events/hour). Independent sample t-tests were utilized to determine differences in blood pressure and TTE measurements between OSA and non-OSA groups (α=0.05). Results Systolic BP was similar in non-OSA vs. OSA groups (131±12 vs. 135±16 mmHg, p=0.443), while diastolic BP was higher in former NFL players with OSA (78±8 vs. 86±9 mmHg, p=0.007). Ejection fraction, left atrial size, left ventricular size, and left ventricular thickness were similar between groups (p&gt;0.05 for all). However, ascending aortic diameter was modestly larger in former NFL players with OSA (3.3±0.19 vs. 3.5±0.40 cm, p=0.048). Conclusion These findings suggest OSA may be a primary driver of increased BP and increased aortic diameter in former NFL players, and impact cardiac structural health, suggesting augmented CVD risk in former NFL players. Future work is warranted to investigate impact of race and player position on OSA-mediated CVD risk in retired NFL players. Support (if any) NFL Players Association, NIH T32-DK007013, and the American Heart Association (24POST1241616)
0851 Effectiveness and Safety of Low-Sodium Oxybate in Idiopathic Hypersomnia Participants: Results from the DUET Study
Cairns, Alyssa , Schneider, Logan , Nichols, Deborah A. , Steininger, Teresa L. , Kirby, Melanie, Akerman, Sarah , Alexander, Jessica, Whalen, Marisa, Ruoff, Chad , Ruoff, Chad M , Plante, David T. , Fuller, Douglas, Kirby, M

Mayo Clinic

SLEEP | May 19, 2025 | Volume: 48 | Issue: Supplement_1 | Pages: A369-A369

10.1093/sleep/zsaf090.0851 Get It

Abstract Introduction Introduction: Jazz DUET (Develop hypersomnia Understanding by Evaluating low-sodium oxybate Treatment) is a phase 4, prospective, multicenter, single-arm, multiple-cohort, open-label study (NCT05875974) evaluating the effectiveness of low-sodium oxybate (LXB, Xywav®) treatment on daytime and nighttime symptoms, including excessive daytime sleepiness (EDS) and polysomnography in participants with idiopathic hypersomnia (IH) or narcolepsy. Data presented are from the IH cohort. Methods DUET included screening (with 2-week washout for oxybate users), 8-day baseline (BL), 2- to 8-week LXB titration, 2-week stable-dose, 8-day end-of-treatment (EOT), and 2-week safety follow-up periods. The primary endpoint was change in Epworth Sleepiness Scale (ESS) score from BL to EOT. Secondary endpoints for the IH cohort included change in Idiopathic Hypersomnia Severity Scale (IHSS) total score, Patient Global Impression of Change (PGIc)−overall IH disease, PGIc−sleep inertia, and Patient Global Impression of Severity (PGIs)−sleep inertia. Exploratory endpoints included IHSS component scores (daytime functioning, sleep inertia). Primary and key secondary (IHSS total score) endpoints were controlled for multiplicity with sequential testing; all other P-values are considered nominal. Results Forty-six people with IH enrolled and were dosed with LXB; 40 were completers. Enrolled participants were mostly female (80.4%) and White (84.8%), with a mean (SD) age of 38.1 (11.8) years. For completers, BL mean (SD) ESS score and IHSS total score were 16.5 (2.7) and 32.9 (7.1), respectively; least-squares mean (LSM) (SE) changes from BL to EOT were −8.4 (0.7), P&lt;.0001 and −15.5 (1.5), P&lt;.0001. BL mean (SD) IHSS component scores for daytime functioning and sleep inertia were 17.7 (4.2) and 10.7 (3.1), respectively; LSM (SE) changes from BL to EOT were −8.8 (1.0), P&lt;.0001 and −4.8 (0.4), P&lt;.0001. At EOT, most participants reported improvement (very much, much, minimally) on PGIc−overall IH disease (94.6%) and PGIc−sleep inertia (81.1%). At BL, 25.0% of participants reported sleep inertia severity as very mild/mild/not present on PGIs–sleep inertia vs 59.0% at EOT. Treatment-emergent adverse events were consistent with the known safety profile of LXB. Conclusion People with IH taking open-label LXB showed improvements in EDS and sleep inertia (decreased ESS and IHSS component scores) and reported reduced multi-symptom burden (decreased IHSS total scores and improved PGIc/PGIs ratings). Support (if any) Jazz Pharmaceuticals